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Abstract 
This study found that MS-275, a novel synthetic benzamide histone deacetylase 
inhibitor (HDACI), blocked Akt/mTOR signaling in acute myelogenous leukemia 
(AML) HL60 and acute promyelocytic leukemia (APL) NB4 cells, as assessed by 
decreased levels of the phosphorylated (p)-Akt, p-p70 ribosomal S6 kinase (p70S6K), 
and p-S6K by Western blot analysis. Interestingly, further inactivation of mTOR by 
rapamycin analogue RAD001 (everolimus) significantly enhanced MS-275-mediated 
growth inhibition and apoptosis of these cells in parallel with enhanced upregulation of 
p27 kip1 and downregulation of c-Myc. In addition, RAD001 potentiated the ability of 
MS-275 to induce differentiation of HL60 and NB4 cells, as measured by expression of 
CD11b cell surface antigens, as well as reduction of nitroblue tetrazolium. Importantly, 
RAD001 potentiated the ability of MS-275 to induce expression of the myeloid 
differentiation-related transcription factor CCAAT enhancer binding protein ε in these 
cells in association with enhanced acetylation of histone H3 on its promoter. 
Furthermore, RAD001 (5 mg/kg) significantly enhanced the effects of MS-275 (10 
mg/kg) to inhibit proliferation of HL60 tumor xenografts in nude mice without adverse 
effects. Taken together, concomitant administration of a HDACI and a mTOR inhibitor 
may be a promising treatment strategy for the individuals with a subset of human 
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leukemia. 
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Introduction 
Acute myelogenous leukemia (AML) is a lethal disease, resulting from the 
clonal expansion and accumulation of hematopoietic stem cells arrested at various 
stages of development.1 Intensification of chemotherapy has led to remissions in 
70-85% of individuals with AML; and post-remission relapses occur frequently.2,3 
Recent studies found that the genotype of mutant nucleophosmin (NPM1) without FLT3 
internal tandem duplications and the mutant CCAAT/enhancer binding protein α 
(CEBPA) were significantly associated with complete remission in the individuals with 
cytogenetically normal AML.4 In addition, these studies found that individuals with 
wild-type NPM1 benefited from hematopoietic stem cell transplantation from an 
HLA-matched related donor4; however, regimen-related toxicities and relapse remain 
serious problems.5 
Histone deacetylase inhibitors (HDACIs) have emerged as a potentially 
promising new class of anticancer drugs.6 These include the hydroxamic acid-derived 
suberoylanilide hydroxamic acid (SAHA, Vorinostat), LBH 589, tricostatin A (TSA), 
cyclic depsipeptide FR901228, valproic acid and the benzamide MS-275.7 HDACIs 
induce growth arrest and apoptosis of cancer cells by manipulating the transcription of 
genes involved in regulation of the cell cycle and apoptosis, as well as differentiation.6 
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For example, we previously showed that SAHA and MS-275 induced growth arrest and 
apoptosis of human mantle cell lymphoma and adult T-cell leukemia cells, respectively, 
in association with induction of histone acetylation of the p21waf1 promoter region, 
resulting in upregulation of the p21waf1 protein.7,8 
Promyelocytic leukemia/retinoic acid receptor α (PML/RARα) fusion protein, 
generated by chromosomal translocation in acute promyelocytic leukemia (APL) 
recruits histone deacetylase (HDAC) and repressor complexes on retinoic acid (RA) 
target promoters and silences RA signaling, resulting in differentiation block of 
hematopoietic stem cells.9 RA, at pharmacological concentration, dissociates HDAC 
and repressor complexes and recruits co-activators to the promoter and activates RA 
signaling, resulting in terminal differentiation.9 HDACI modifies chromatin structure 
and increases promoter accessibility, leading to transcriptional activation.10 HDACI 
increased sensitivity of APL cells to RA-induced differentiation.11 
Valproic acid (VPA), the antiepileptic drug, induced differentiation and apoptosis 
of AML cells in a murine model via inhibition of HDAC.12 The clinical efficacy of 
VPA as monotherapy or in combination with all-trans-retinoic acid (ATRA) has 
recently been shown in the individuals with AML and myelodysplastic syndromes.13   
The CCAAT enhancer binding protein ε (C/EBPε) is a family of transcription 
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factors that regulates proliferation and differentiation of numerous cell types including 
granulocytes.14,15 We and others previously showed that C/EBPε is pivotal to 
granulocytic differentiation.16,17 C/EBPε modulates levels of various cell cycle 
regulating molecules during differentiation; over-expression of C/EBPε down-regulated 
levels of c-Myc and up-regulated levels of cyclin-dependent kinase inhibitor p27kip1 in 
myeloid cells.18,19  
The serine/threonine kinase mammalian target of rapamycin (mTOR) is 
activated by PI3K/Akt signaling and regulates cell proliferation in part by ribosomal 
protein translation and the initiation of cap-dependent translation.20,21 mTOR 
phosphorylates p70 ribosomal S6 kinase (p70S6K) and eukaryotic initiation factor 
4E-binding protein-1 (4E-BP-1) and increases the translation of mRNAs with long, 
highly structured 5’-untranslated regions, such as cyclin D1 and c-Myc which regulate 
cell cycle transition from G1 to S phase.20,21 The mTOR inhibitors, rapamycin or its 
analog RAD001 (everolimus) have been shown to be active against many types of solid 
tumors as well as subsets of leukemia, and are now being under evaluation in clinical 
trials.22 
This study found that MS-275 induced growth arrest, apoptosis, and 
differentiation of AML cells in association with blockade of mTOR signaling. Further 
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inhibition of mTOR signaling by RAD001 significantly potentiated the ability of 
MS-275 in AML cells in vitro and in vivo. Notably, RAD001 augmented 
MS-275-mediated acetylation of histone H3 on C/EBPε promoter, resulting in enhanced 
upregulation of C/EBPε in AML cells. Moreover, RAD001 significantly enhanced 
MS-275-inducded growth inhibition of HL60 tumor xenografts in nude mice without 
adverse effects.   
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Materials and Methods 
Reagents. MS-275 and RAD001 were provided by Schering AG (Berlin, Germany) and 
Novartis (Basel, Switzerland), respectively. These reagents were dissolved in 100% 
dimethyl sulfoxide (DMSO) to a stock concentration of 10-2 M and stored at -80°C. For 
animal studies, RAD001 and MS-275 were diluted in double-distilled water just before 
administration by gavage.  
Cells. HL60 cells were obtained from American Type Culture Collection (ATCC, 
Manassas, VA). NB4 cell line was a kind gift from M. Lanotte (St Louis Hospital, Paris, 
France). Cells were grown in RPMI 1640 containing 10% fetal bovine serum.  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Cells 
(5x105 /mL) were cultured with various concentrations of MS-275 (0.1-1 μM) and/or 
RAD001 (3-100 nM ) for 2 days in 96-well plates. MTT assay was performed as 
previously described.23 All experiments were performed in triplicate and repeated at 
least three times.  
Cell cycle analysis by flow cytometry. Cell cycle analysis was performed on HL60 and 
NB4 cells incubated with various concentrations of either MS-275 and/or RAD001, as 
previously described.24  
Apoptosis assays. The ability of MS-275 and/or RAD001 to induce apoptosis in 
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leukemia cells was measured using the annexin V-FITC apoptosis detection kit 
(Pharmingen, Inc., San Diego, CA), as previously described.25 
Assays for differentiation of leukemia cells. The HL60 and NB4 cells (5x105/ml) 
were seeded in 12-well plates and were cultured with various concentrations of either 
MS-275 and/or RAD001. After 2 days, expression of CD11b on their cell surface was 
measured by staining with a Fluorescein (FITC)-cojugated anti-CD11b mAb (Dako, 
Glostrup, Denmark) using flow cytometry. For NBT measurements, cells (5×105/mL) 
were incubated in 12-well plates (Corning, Corning, NY) for 2 days as described above. 
After incubation, each cell suspension was mixed with an equal volume of RPMI 1640 
containing 1 mg/ml NBT (Sigma) and 10-6 mol/L 12-0-tetradecanoyl-13-acetate (TPA; 
Sigma) for 20 minutes at 37°C. The cells were washed in phosphate-buffered saline 
(PBS), cytocentrifuged, fixed in methanol for 5 minutes, and stained with Gram safranin 
for 10 minutes at room temperature; 300 cells were analyzed for blue dye using light 
microscopy, as previously described.26 
Western blot analysis. Western blot analysis was performed as described previously.27 
The membrane was probed sequentially with the antibodies. Anti-Akt (Cell Signaling 
Technology, Beverly, MA), p-Akt (Cell Signaling Technology), p-ERK (Cell Signaling 
Technology), ERK (Cell Signaling Technology), p27kip1 (Santa Cruz Biotechnology, 
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Santa Cruz, CA) C/EBPε (Santa Cruz Biotechnology), c-Myc (Santa Cruz 
Biotechnology), p70S6K (Cell Signaling Technology), p-p70S6K (Cell Signaling 
Technology), S6K (Cell signaling Technology), p-S6K (Cell Signaling Technology) and 
-α-tubulin (Santa Cruz Biotechnology) antibodies were used. 
Chromatin immunoprecipitation (Chip) assay. NB4 and HL60 cells (1x106/ml) were 
cultured with MS-275 (0.3 μM) and/or RAD001 (10 nM) for 2 days. Untreated cells 
were used as controls. Formaldehyde was added to the cells to a final concentration of 
1%, and the cells were incubated at 37℃ for 10 min. The cells were collected and 
subjected to chromatin immunoprecipitation utilizing reagents provided by LPBIO 
(Lake Placid, NY), as previously described.28 Anti-acetylated histone H3 antibody 
(Upstate) was used for immunoprecipitation. Immunoprecipitated DNA was recovered 
and used as a template for real-time-PCR. The primers for C/EBPε promoter were as 
follows: forward, 5’-GGAAAAGGAAGCAGAGCAGA-3’, reverse, 
5’-TCGATCTTCTGCCCTAGACC-3’. Real-time PCR was carried out by using Power 
SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), as previously 
described.29 The amplified sequences were normalized to those form cross-linked 
DNA/protein complexes which were not immunoprecipitated with anti-acetylated 
histone H3 antibody, as previously described.30  
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Mice. Female immune deficient BALB/c nude mice at 4 weeks of age were purchased 
from JAPAN SLC. Inc. (Shizuoka, Japan), and were maintained in pathogen-free 
conditions with irradiated chow. Animals were bilaterally, subcutaneously (s.c.) injected 
with 2 x 10
6 
HL60 cells/tumor in 0.1 ml Matrigel (Collaborative Biomedical  
Products, Bedford, MA). When HL60 cells formed palpable tumors, mice were divided 
randomly into four groups receiving control (n=5), or either RAD001 (n=5) or MS-275 
(n=5), or combination of both RAD001 and MS-275 (n=5). MS-275 (10mg/kg) was 
given to mice by oral administration six times during two weeks. RAD001 (5mg/kg) 
was given to mice by oral administration four times during a week. The dose of these 
agents was determined by our preliminary studies (data not shown). Control diluent was 
given to the untreated control mice. Body weight and tumors were measured twice a 
week. Tumor sizes were calculated by the formula: a x b x c, where “a” is the length and 
“b” is the width and “c” is the height in millimeters. At the end of the experiment, 
animals were sacrificed by CO
2 
asphyxiation and tumor weights were measured after 
their careful resection. Tumor tissue was collected for analysis. The experiments were 
approved by the Review Board of Kochi University.  
Statistical Analysis. Statistical analysis was performed to assess the difference between 
two groups under multiple conditions by one-way ANOVA followed by Boneferroni’s 
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multiple comparison tests using PRISM statistical analysis software (GraphPad 
Software, Inc., San Diego, CA). 
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Results. 
MS-275 inhibits Akt/mTOR signaling in AML cells. Exposure of HL60 and NB4 
cells to MS-275 (0.1-1 μM, 48 hrs) inhibited their proliferation with the concentration 
that inhibits cell proliferation by 50 % (IC50) values of approximately 0.8 and 0.9 μM, 
respectively as measured by MTT assay (figure not shown). Western blot analyses 
showed that both HL60 and NB4 cells constitutively expressed phosphorylated forms of 
Akt and mTOR substrates p70S6K and S6K (Fig 1). Exposure of these cells to MS-275 
(0.1-1 μM, 48 hours) effectively down-regulated levels of the phosphorylated forms of 
Akt, p70S6K, and S6K without modulating total amount of these proteins, suggesting 
that MS-275 inhibited the activation of the mTOR signal pathway (Fig 1). These cells 
also constitutively expressed phosphorylated forms of ERK, which was down-regulated 
after exposure to MS-275 (0.1-1 μM, 48 hours); however, effects of MS-275 (0.3 or 1 
μM) on p-ERK appeared to be less potent compared to those on Akt signaling (Fig 1). 
Blockade of mTOR signaling potentiates the ability of HDACI to inhibit 
proliferation of AML cells. MS-275 blocked Akt/mTOR signaling in AML cells (Fig 1). 
We, therefore, explored the drug interaction of MS-275 and RAD001, the inhibitor of 
mTOR in these cells. RAD001 (10 nM) significantly potentiated the ability of MS-275 
(0.1-1 μM) to inhibit the proliferation of HL60 and NB4 cells as measured by MTT 
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assay on the second day of culture (Figs. 2A, B)   
Blockade of mTOR signaling potentiates the ability of MS-275 to induce apoptosis 
of leukemia cells. Cell cycle analysis showed that exposure of HL60 and NB4 cells to 
MS-275 (1 μM, 48 hrs) induced accumulation of cells in the pre-G1 phase of the cell 
cycle, a feature characteristic of apoptosis (Figs. 2C, D). RAD001 (10 nM, 48 hrs) alone 
did not induce accumulation of cells in pre-G1 phase of cell cycle; however, when 
MS-275 was combined with RAD001, the proportion of cells in pre-G1 phase of the cell 
cycle dramatically increased compared to either alone (p<0.01) with respect to either 
compound alone; Figs. 2 C, D. For example, either MS-275 (1 μM, 48 hrs) or RAD001 
(10 nM, 48 hrs) alone caused an accumulation of 52 ± 10 % and 4 ± 2 % (mean ± SD) 
of HL60 cells in the pre-G1 phase, respectively. When these cells were exposed 
simultaneously to both of these compounds at the same concentration, the proportion of 
cells in the pre-G1 phase of the cell cycle increased to a mean 87 ± 3.8 % (Fig. 2C). 
The ability of RAD001 to enhance MS-275-induced apoptosis of leukemia cells was 
further confirmed by Annexin V staining. Exposure of HL60 cells to MS-275 (1 μM, 48 
hrs) alone resulted in 68 ± 4 % of HL60 cells becoming annexin V positive. On the 
other hand, exposure of HL60 cells to RAD001 (10 nM, 48 hrs) alone did not induce 
apoptosis of HL60 cells. When these cells were exposed to the combination of both at 
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the same concentration, a mean 89 ± 1 % of cells became annexin V positive (p<0.01 
with respect to either compound alone; Fig. 2E). Similarly, MS-275-induced apoptosis 
of NB4 cells was significantly potentiated in the presence of RAD001 (Fig. 2F).  
RAD001 enhanced MS-275-induced differentiation of AML cells. We examined the 
ability of MS-275 to induce differentiation of AML cells by quantifying CD11b 
expressing population, a marker of myeloid differentiation, by flow cytometry. 
Exposure of HL60 or NB4 cells to MS-275 (0.1 or 0.3 μM) for 48 hrs induced 
expression of CD11b antigen on their cell surface in a dose-dependent manner. Effect of 
RAD001 on the expression of CD11b was negligible; however, when MS-275 (0.1 or 
0.3 μM) was combined with RAD001 (10 nM), proportion of cells expressing CD11b 
antigen was dramatically increased (Figs. 3A, B). The production of superoxide is a 
marker of granulocyte-like differentiation, which can be measured by the ability to 
reduce NBT.25 Using this marker, we examined the ability of MS-275 and RAD001 in 
combination to induce differentiation of HL-60 and NB4 cells. MS-275 at either 0.1 or 
0.3 μM, (48 hrs) induced 11± 2 and 14 ± 2 % of HL-60 cells to reduce NBT, 
respectively. RAD001 (10 nM, 48 hrs) alone induced 7 ± 1 % of cells to reduce NBT. 
When both compounds were combined at the same concentration, a mean of 32 % or 
39 % of HL-60 cells reduced NBT (Fig. 3C). Similarly, RAD001 (10 nM, 48 hrs) 
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enhanced the ability of MS-275 (0.1 μM, 48 hrs) to reduce NBT in NB4 cells (Fig. 3D). 
However, when higher dose of MS-275 (0.3 μM) was combined with RAD001 (10 nM), 
proportion of cells with reduced NBT decreased (Fig. 3D), mainly because cells 
underwent apoptosis rather than differentiation (data not shown).  
Effect of MS-275 and RAD001 on expression of proteins important in regulating 
cell cycle and differentiation in leukemia cells. We next examined whether MS-275 
and RAD001 modulated levels of C/EBPε, c-Myc, and p27kip1 in leukemia cells by 
Western blot analysis (Fig. 4). Exposure of HL60 and NB4 cells to either MS-275 (0.1 
μM, 48 hrs) or RAD001 (10 nM, 48 hrs) alone slightly induced expression of C/EBPε 
and p27kip1. When HL60 and NB4 cells were exposed to the combination of both at the 
same concentration, levels of these proteins were markedly up-regulated (Fig. 4A). 
Effect of MS-275 (0.3 μM, 48 hrs) or RAD001 (10 nM, 48 hrs) on levels of c-Myc was 
negligible in NB4 and HL60 cells; however, combination of both compounds at the 
same concentration dramatically down-regulated levels of c-Myc in these cells (Fig. 4A). 
MS-275 in combination with RAD001 completely blocked expression of p-S6K and 
p-p70S6K in these cells (Fig. 4B), suggesting that mTOR signaling was effectively 
blocked. 
RAD001 enhanced MS-275-induced acetylation of histone H3 on the C/EBPε 
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promoter in leukemia cells. HL60 and NB4 cells were cultured in the presence of 
either MS-275 (0.1 or 0.3 μM) and/or RAD001 (10 nM) for 48 hrs. Western blot 
analyses showed that MS-275, but not RAD001, slightly induced acetyl-histone H3 
proteins in NB4 cells (Fig. 5A). Both of MS-275 and RAD001 slightly induced 
acetyl-histone H3 proteins in HL60 cells (Fig. 5A). When these cells were exposed to 
both agents at the same concentration, levels of acetyl-histone H3 dramatically 
increased (Fig. 5A). 
We next examined the effect of MS-275 and RAD001 in combination on acetylation of 
histone H3 around the C/EBPε gene by ChIP assay. To quantify acetylated DNA 
precisely, we employed real-time PCR. As shown in Fig. 5B, exposure of HL60 and 
NB4 cells to RAD001 (10 nM) and MS-275 (0.1 μM) in combination for 48 hrs 
prominently enhanced acetylation of histone H3 on the C/EBPε promoter in these two 
cell lines.  
RAD001 enhanced the ability of MS-275 to inhibit the proliferation of human 
HL60 leukemic xenografts in vivo. We further evaluated the anti-proliferative activity 
of MS-275 combined with RAD001 in vivo (Fig. 6). MS-275 (10 mg/kg) or RAD001 (5 
mg/kg) alone inhibited the proliferation of HL60 xenografts by approximately 40 % or 
50 %, respectively compared to control tumors (Fig. 6A). When mice were treated with 
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both compounds, tumor growth was inhibited by nearly 75 % (Fig. 5A), resulting in 
decreased weights of HL60 tumors at autopsy (Fig. 6B). None of the treated mice show 
signs of illness or significant weight loss (Fig. 6C).  
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Discussion 
This study, for the first time, showed that inhibition of mTOR dramatically 
potentiated the ability of HDACI to acetylate histone H3 in leukemia cells (Fig 5). 
RAD001 markedly increased MS-275-stimulated acetylation of histone H3 on C/EBPε 
promoter and enhanced its expression in HL60 and NB4 cells (Figs 4, 5, 7), which was 
associated with increased differentiation of these cells (Fig 3). In parallel, MS-275 in 
combination with RAD001 upregulated levels of p27kip1 and downregulated levels of 
c-Myc proteins (Figs 4, 7). 
MS-275-induced growth arrest, apoptosis, and differentiation of AML cells 
appeared to be dose-dependent. Low dose of MS-275 (0.1 or 0.3 μM) induced 
differentiation of these cells in association with increased levels of C/EBPε (Figs 3, 4). 
When these cells were exposed to higher dose of MS-275 (1 μM), induction of 
apoptosis was prominent in parallel with blockade of Akt/mTOR signaling (Figs 1, 2). 
Similarly, previous studies showed that MS-275 exerted dose-dependent effects in 
human leukemia cells (U937, HL60, K562 and Jurkat); it induced growth arrest and 
differentiation of leukemia cells at low concentrations. On the other hand, higher dose 
of MS-275 caused marked apoptosis of leukemia cells.31 These investigators showed 
that high dose of MS-275 generated reactive oxygen species (ROS) in leukemia cells 
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followed by the loss of mitochondrial membrane potential and cytosolic release of 
cytochrome c, resulting in activation of the caspase cascade and apoptosis.31 Another 
study also found that MS-275 produced ROS and activated caspases, leading to 
apoptosis of chronic lymphocytic leukemia cells.32 We have recently shown that 
MS-275 inhibited the nuclear factor κ B, which stimulated a variety of anti-apoptotic 
molecules such as bcl-2 family members, and induced growth arrest and apoptosis of 
adult T-cell leukemia cells.8 
We have recently shown that SAHA (vorinostat), one of the HDACI derived from 
hydroxamic acid, also inhibited Akt/mTOR signaling, resulting in downregulation of 
cyclin D1 in mantle cell lymphoma cells.33 In addition, other investigators found that 
SAHA, as well as, TSA inhibited Akt activity in prostate cancer cells.34 These 
observations suggested that Akt signal pathway may be a common target of HDACI. 
The Akt/mTOR signal pathway negatively regulates granulocytic differentiation; 
all-trans retinoic acid (ATRA) induced myeloid differentiation of APL cells in 
conjunction with inactivation of the Akt/mTOR signal pathway.35,36 We have recently 
identified RTP801, the stress responsive gene, as one of the ATRA-target genes 
responsive to ATRA-mediated differentiation of AML cells. RTP801 is a negative 
regulator of the mTOR pathway.37 It is unlikely that MS-275 induced differentiation of 
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AML cells and inhibited mTOR signaling via RTP801. MS-275 inhibited both Akt and 
mTOR (Fig 1); however, RTP801 was shown to inhibit mTOR but not Akt.38  
The MEK/ERK signal pathway is another prosurvival signal pathway activated in 
AML. We have recently shown that MS-275 also inhibited MEK/ERK signaling in 
AML cells. Interestingly, further inactivation of MEK/ERK signaling by AZD6244 
enhanced MS-275-mediated acetylation of histone H3 on p21waf1 promoter, resulting in 
marked upregulation of p21waf1 protein and induction of apoptosis of AML cells.28 
Contrary to this study, inhibition of MEK/ERK signaling blunted MS-275-induced 
differentiation of AML cells.28   
Taken together, the combination of MS-275 and RAD001 may be useful for 
treatment of individuals with a subset of AML. Further studies are required to verify the 
molecular mechanisms by which blockade of mTOR signaling affects chromatin 
remodeling. 
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Figure Legend 
Fig.1. Western blot Analysis. HL60 and NB4 cells were cultured with MS-275 (0.1-1 
μM) for 3 hrs. Western blot analysis was utilized to monitor the levels of Akt, p-Akt, 
S6K, p-S6K, p70S6K, p-p70S6K and α-tubulin. Each lane was loaded with 30 μg of 
protein. The figure represents one of the three experiments performed independently 
with similar results. 
Fig.2. RAD001 potentiates the action of MS-275 in leukemia cells. MTT assay. (A) 
HL60 and (B) NB4 cells were cultured with either MS-275 (0.1-1 μM) and/or RAD001 
(10 nM). After 2 days, cell proliferation was measured by MTT assay. The statistical 
significance of difference between growth inhibition induced by either MS-275 or 
RAD001 alone and those induced by a combination of both was determined by one-way 
analysis of variance (ANOVA) followed by Boneferroni’s multiple comparison tests. 
Results represent the mean ± SD of 3 experiments performed in triplicate. *, p<0.01, 
with respect to control. Cell cycle analysis. (C) HL60 and (D) NB4 cells were cultured 
with MS-275 or RAD001 either alone or in combination. After 2 days, the cell cycle 
distribution of these cells was analyzed. Results represent one of the three experiments 
performed in duplicate. RAD001 enhanced MS-275-inducing apoptosis. (E) HL60 
and (F) NB4 cells were cultured with MS-275 (0.1-1 μM) or RAD001 (10 nM) either 
Nishioka, et al. 
 32
alone or in combination. After 2 days, cells were stained with annexin-V/ propidium 
iodide, and analyzed by flow cytometry. The statistical significance of difference 
between annexin V positive populations induced by either MS-275 or RAD001 alone 
and those induced by combination of both was determined by ANOVA followed by 
Boneferroni’s multiple comparison tests. Results represent the mean (SD of 3 
experiments performed in triplicate; *, p< 0.01, with respect to control. 
Fig.3. The effect of RAD001 on MS-275-induced expression of CD11b in leukemia 
cells. HL60 (A) and NB4 (B) cells were cultured with either MS-275 (0.1 or 0.3 μM) 
and/or RAD001 (10 nM). After 2 days, CD11b expressing population was measured by 
FACScan. Results represent one of the experiments performed twice in duplicate plate.  
The effect of RAD001 on MS-275-induced NBT reduction in leukemia cells. HL60 
(C) and NB4 (D) cells were cultured with either MS-275 (0.1 or 0.3 μM) and/or 
RAD001 (10 nM) for 2 days, and differentiation was determined by NBT reduction. 
The statistical significance of difference between NBT reduction induced by either 
MS-275 and/or RAD001 was determined by ANOVA followed by Boneferroni’s 
multiple comparison tests. Results represent the mean of 3 experiments performed in 
triplicate; *, p< 0.01, with respect to control.  
Fig.4. Western blot Analysis. HL60 and NB4 cells were cultured with either MS-275 
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(0.1 or 0.3 μM) and/or RAD001 (10 nM) for 48 hrs (A) or 3 hrs (B). Western blot 
analysis was performed to monitor the levels of (A) C/EBPε, c-Myc, p27kip1, (B) S6K, 
p-S6K, p70S6K, p-p70S6K and α-tubulin. Each lane was loaded with 30 μg of proteins.  
Fig.5. RAD001 enhanced MS-275-induced acetylation of histone H3. (A) HL60 and 
NB4 cells were cultured in the presence of either MS-275 (0.1 or 0.3 μM) and/or 
RAD001(10 nM). After 48 hrs, cells were harvested and nuclear proteins were prepared 
and subjected to Western blot analysis. The membranes were sequentially probed with 
anti-acetyl-histone H3 and anti-histone H1 antibodies. Ac-histone H3, 
acetylated-histone H3. Chromatin immunoprecipitation assay. (B) Acetylation of 
histone H3 in the C/EBPε promoter was analyzed by chromatin immunoprecipitation 
assay. HL60 and NB4 cells were cultured in the presence of either MS-275 (0.1 μM) 
and/or RAD001 (10 nM). After 48 hrs, cells were harvested and subjected to chromatin 
immunoprecipitation followed by real-time PCR. The amplified sequences were 
normalized to those form input (the cross-linked DNA/protein complexes which were 
not immunoprecipitated with anti-acetylated histone H3 antibody). The statistical 
significance of difference between acetylation of histone H3 induced by either MS-275 
and/or RAD001 was determined by ANOVA followed by Boneferroni’s multiple 
comparison tests. Results represent the mean of 4 experiments performed in duplicate; *, 
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p< 0.01, with respect to control.  
Fig 6. Effect of co-administration of MS-275 and RAD001 on the proliferation of 
HL60 cells in murine xenograft model. (A), HL60 cells were injected bilaterally s.c. 
into BALB/c nude mice, forming two tumors/mouse. When HL60 tumors were palpable 
(approximately 50 mm3), mice were randomized into four groups (n=5) and treatment 
was initiated. MS-275 (10 mg/kg) was administered to mice by oral administration six 
times every another day. RAD001 (5 mg/kg) was given four times every another day. 
Tumor volumes were measured twice a week. Each point represents the mean ± SD of 
10 tumors. (B), Tumor weights at autopsy. After 2 weeks of treatment, tumors were 
removed and weighed. Results represent mean ± SD of tumor weights. Statistical 
significance was determined by one-way ANOVA followed by Boneferroni’s multiple 
comparison tests. Bars, SD. (C), Body weight. Body weight of mice was measured 
twice a week during treatment. cont, diluent control.  
Fig 7. RAD001 potentiates the action of MS-275. (A), RAD001 enhances 
MS-275-induced acetylation of histone H3 on the promoter of C/EBPε, resulting in 
enhanced up-regulation of this transcription factor and induction of differentiation of 
AML cells. (B), Both RAD001 and MS-275 targets Akt/mTOR signaling in AML cells. 
Combination of both down-regulated levels of c-Myc, resulting in growth inhibiton. Ac, 
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acetylation, H3, histone H3.   
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